Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor

BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...

Full description

Saved in:
Bibliographic Details
Published in:Pediatr Pulmonol
Main Authors: Singh, Sachinkumar B., McLearn-Montz, Amanda J., Milavetz, Francesca, Gates, Levi K., Fox, Christopher, Murry, Logan T., Sabus, Ashley, Porterfield, Harry S., Fischer, Anthony J.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/
https://ncbi.nlm.nih.gov/pubmed/31012285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items